News >

Adjuvant Axitinib Falls Short in Phase III RCC Trial

Jason M. Broderick @jasoncology
Published: Wednesday, Apr 11, 2018

Dr. Mace Rothenberg

Mace Rothenberg, MD
Adjuvant axitinib (Inlyta) did not extend disease-free survival (DFS) versus placebo for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, according to findings from the phase III ATLAS trial.

Another VEGFR TKI, sunitinib (Sutent), previously demonstrated success in this setting. In results from the phase III S-TRAC trial, which were presented at the 2016 ESMO Congress and published in the New England Journal of Medicine,1,2 adjuvant sunitinib prolonged DFS by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell RCC. Based on these findings, the FDA approved sunitinib in November 2017 for use in this setting. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication